Information for the public

Cabozantinib (Cometriq) is available on the NHS as a possible treatment for progressive medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.

Information and support

NHS Choices may be a good place to find out more.

These organisations can give you advice and support:

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2887-3


This page was last updated: 28 March 2018